Heron Therapeutics Inc (HRTX)

Over the past six months, Heron Therapeutics' stock price has been impacted by several events. The company reported Q1 earnings and revenues that topped estimates and settled patent litigations with Mylan Pharma regarding CINVANTI and APONVIE in May 2025. In June 2025, a new analyst forecast gave HRTX a $6.0 price target and HC Wainwright & Co. initiated coverage with a Buy recommendation. In August 2025, the company reported a Q2 loss and missed revenue estimates, but Q2 acute care revenue jumped 56%. Heron Therapeutics announced it expected to receive approximately $62.7 million in funding, entered into a board agreement, and completed refinancing transactions. The company also signed a new headquarters lease and adopted a tax benefits preservation plan to protect $1.37 billion in NOLs. In September 2025, Heron Therapeutics filed a $125M mixed securities shelf and also filed to sell 37.91M shares of common stock for holders. The stock surged by 6.6% after a positive earnings update and stronger-than-expected oncology product revenue growth. The average one-year price target for HRTX was revised down by 24% to $4.84 in August 2025. Heron Therapeutics is scheduled to report its Q3 2025 financial results on Tuesday, November 4, 2025. The stock has experienced volatility, with a 52-week range between $1.04 and $2.68, closing at $1.19 as of October 23, 2025.

Information specifically detailing the demand seasonality for Heron Therapeutics' products and services is limited. General seasonality analysis for HRTX stock suggests that for October, the historical bias leans long, with the next statistically strong window culminating around October 16, 2026. The company's focus on acute care and oncology patients suggests a more consistent demand driven by medical necessity rather than strong seasonal fluctuations, though specific product launches or clinical trial results could create temporary demand spikes.

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing pharmaceutical products for acute care and oncology patients, addressing unmet medical needs in pain management and supportive care. The company operates within the Health Technology sector and the Biotechnology industry, leveraging its Biochronomer drug delivery technology for sustained release of therapeutic agents. Key products include SUSTOL for chemotherapy-induced nausea and vomiting (CINV), CINVANTI for CINV, ZYNRELEF for postoperative pain management, APONVIE for postoperative nausea and vomiting (PONV), HTX-011 for post-operative pain, HTX-019 for acute CINV prophylaxis, and HTX-034 for postoperative pain.

Heron Therapeutics primarily serves the U.S. market and is pursuing global partnerships to expand its geographic footprint. The company is headquartered in Cary, North Carolina, with a previous location in San Diego, California.

Heron Therapeutics is focused on improving patient lives through innovative therapies in pain management and supportive care. The company's research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management, aiming to improve patient outcomes and reduce reliance on opioids. The Q2 loss and missed revenue estimates could negatively impact investor confidence, while the settlement of patent litigations with Mylan Pharma regarding CINVANTI and APONVIE could be viewed positively. Heron Therapeutics has a consensus "Hold" rating from Wall Street analysts. The stock has underperformed the US Biotechs industry and the US Market over the past year. Operational restructuring and improved financial flexibility are seen as positive for efficient growth and enhanced margins.

80.01% of Heron Therapeutics' shares are held by institutional shareholders, while 5.86% are held by insider shareholders. Public companies and individual investors hold 99.95% of the ownership, with mutual funds holding 0.05% and other institutional investors holding less than 0.01%. Major institutional owners include ETFs such as Vanguard Health Care ETF (VHT), iShares Micro-Cap ETF (IWC), and Invesco NASDAQ Future Gen 200 ETF (QQQS). Rubric Capital bought Heron Therapeutics (HRTX) shares worth $3.5 million.